• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veraxa Biotech AG - Ordinary Shares (NQ:VRXA)

1.260 +0.170 (+15.60%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Veraxa Biotech AG - Ordinary Shares

< Previous 1 2 Next >
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
October 07, 2026
Via Investor Brand Network
Topics Animal Testing
News headline image
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
October 07, 2026
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs 
From Veraxa Biotech AG
Via GlobeNewswire
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage
September 29, 2026
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress
September 24, 2026
Via Investor Brand Network
Topics Intellectual Property
VERAXA Biotech AG (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
September 21, 2026
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
September 17, 2026
Via Investor Brand Network
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Developing Next-Gen Cancer Therapies with Dual-Targeting Approach
September 16, 2026
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy
September 15, 2026
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development
September 10, 2026
Via Investor Brand Network
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer
September 04, 2026
Via Investor Brand Network
News headline image
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
September 04, 2026
Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its... 
From Veraxa Biotech AG
Via GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
August 27, 2026
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Report Positive Early Results From Antibody Oligonucleotide Collaboration
August 24, 2026
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase
August 24, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
August 24, 2026
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise 
From Veraxa Biotech AG
Via GlobeNewswire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy
August 21, 2026
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision
August 21, 2026
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology
August 18, 2026
Via Investor Brand Network
Topics Artificial Intelligence
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology
August 18, 2026
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market
August 07, 2026
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
August 05, 2026
Via Investor Brand Network
Topics Intellectual Property
VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
July 29, 2026
Via Investor Brand Network
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
July 29, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
July 29, 2026
First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology... 
From Veraxa Biotech AG
Via GlobeNewswire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
July 27, 2026
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
July 27, 2026
Via Investor Brand Network
News headline image
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
July 27, 2026
VXA-222 advances into next phase at VERAXA 
From Veraxa Biotech AG
Via GlobeNewswire
News headline image
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
July 24, 2026
From Veraxa Biotech AG
Via GlobeNewswire
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer
July 23, 2026
Via Investor Brand Network
News headline image
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
July 23, 2026
From Veraxa Biotech AG
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap